Drug intelligence / Profile preview

VIA Form+

Development stage: Unknown
Lead developer: Vivex Biologics
Modality: Cell Therapies
Administration: Surgical Implantation

Overview

VIA Form+ is a cellular bone matrix (CBM) allograft developed by Vivex Biologics for use in orthopedic and spinal fusion procedures. The product is a 100% human tissue scaffold composed of demineralized cortical bone fibers and mineralized cancellous bone chips that retain endogenous bone cells. It functions by providing an osteoconductive scaffold and osteoinductive potential, which together support bone regeneration and fusion. VIA Form+ is supplied in a ready-to-use syringe for surgical implantation and is indicated for use as a bone graft substitute in procedures such as lumbar interbody fusion. Clinical data has demonstrated sustained effectiveness and long-term fusion outcomes over a three-year period without significant complications.

Brand names: VIA Form+
Other names: VIA Form Plus

Beyond the preview

Go deeper on VIA Form+.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIA Form+.

Explore the full profile